Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 CAR iNK-T cell
- Development stage
- Preclinical
- Lead developer
- BrainChild Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intracerebroventricular, Intratumoral, Intracavitary, Intraventricular
01
Overview
B7-H3 CAR iNK-T cell is an adoptive cell therapy utilizing invariant natural killer T (iNKT) cells engineered with a Chimeric Antigen Receptor (CAR) targeting B7-H3. This therapy is being investigated for its potential in treating childhood central nervous system (CNS) tumors, such as medulloblastoma. iNKT cells are innate-like T cells that naturally migrate towards CCL2, which is overexpressed in medulloblastoma, potentially overcoming immune cell trafficking limitations into CNS tumors. Additionally, they may neutralize the immune suppressive microenvironment by selectively lysing tumor-associated macrophages. The B7-H3 CAR construct enables these iNKT cells to specifically recognize and target B7-H3 expressing medulloblastoma cells, leading to tumor lysis and improved survival in preclinical models.
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 CAR iNK-T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 CAR iNK-T cell.